A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
Public ClinicalTrials.gov record NCT00160524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032
Study identification
- NCT ID
- NCT00160524
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Pharma SA
- Industry
- Enrollment
- 596 participants
Conditions and interventions
Conditions
Interventions
- Certolizumab Pegol (CDP870) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2004
- Primary completion
- Jul 31, 2012
- Completion
- Jul 31, 2012
- Last update posted
- Jul 31, 2018
2004 – 2012
United States locations
- U.S. sites
- 47
- U.S. states
- 23
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 45102 | Birmingham | Alabama | — | — |
| 45028 | Huntsville | Alabama | — | — |
| 45144 | Tucson | Arizona | — | — |
| 45095 | Orange | California | — | — |
| 45006 | San Diego | California | — | — |
| 45131 | San Diego | California | — | — |
| 45130 | Colorado Springs | Colorado | — | — |
| 45094 | Gainesville | Florida | — | — |
| 45029 | Jacksonville | Florida | — | — |
| 45087 | Miami | Florida | — | — |
| 45085 | Plantation | Florida | — | — |
| 45143 | Atlanta | Georgia | — | — |
| 45064 | Savannah | Georgia | — | — |
| 45138 | Columbus | Indiana | — | — |
| 45111 | Louisville | Kentucky | — | — |
| 45105 | Annapolis | Maryland | — | — |
| 45033 | Chevy Chase | Maryland | — | — |
| 45013 | Laurel | Maryland | — | — |
| 45057 | Plymouth | Minnesota | — | — |
| 45108 | Jefferson City | Missouri | — | — |
| 45031 | Lincoln | Nebraska | — | — |
| 45035 | Berlin | New Jersey | — | — |
| 45124 | Florham Park | New Jersey | — | — |
| 45018 | New Brunswick | New Jersey | — | — |
| 45009 | Great Neck | New York | — | — |
| 45070 | New York | New York | — | — |
| 45117 | Rochester | New York | — | — |
| 45003 | Raleigh | North Carolina | — | — |
| 45040 | Winston-Salem | North Carolina | — | — |
| 45081 | Cincinnati | Ohio | — | — |
| 45091 | Cincinnati | Ohio | — | — |
| 45054 | Dayton | Ohio | — | — |
| 45039 | Oklahoma City | Oklahoma | — | — |
| 45041 | Tulsa | Oklahoma | — | — |
| 45048 | Portland | Oregon | — | — |
| 45084 | Chattanooga | Tennessee | — | — |
| 45113 | Germantown | Tennessee | — | — |
| 45071 | Nashville | Tennessee | — | — |
| 45119 | Nashville | Tennessee | — | — |
| 45022 | Houston | Texas | — | — |
| 45073 | San Antonio | Texas | — | — |
| 45020 | Salt Lake City | Utah | — | — |
| 45139 | Salt Lake City | Utah | — | — |
| 45052 | South Ogden | Utah | — | — |
| 45078 | Christiansburg | Virginia | — | — |
| 45109 | Norfolk | Virginia | — | — |
| 45135 | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 159 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00160524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00160524 live on ClinicalTrials.gov.